USANA Health Sciences (USNA) 10-Q 8 Aug 23 2023 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jul. 01, 2023	Aug. 04, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 01, 2023
Document Transition Report	false
Entity File Number	001-35024
Entity Registrant Name	USANA HEALTH SCIENCES, INC.
Entity Incorporation, State or Country Code	UT
Entity Tax Identification Number	87-0500306
Entity Address, Address Line One	3838 West Parkway Blvd.
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84120
City Area Code	801
Local Phone Number	954-7100
Title of 12(b) Security	Common Stock
Trading Symbol	USNA
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,301,730
Entity Central Index Key	0000896264
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 01, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 300,183	$ 288,420
Inventories	61,962	67,089
Prepaid expenses and other current assets	25,501	28,873
Total current assets	387,646	384,382
Property and equipment, net	95,736	97,773
Goodwill	16,859	17,368
Intangible assets, net	29,997	32,432
Deferred tax assets	15,914	9,799
Other assets	56,528	54,795
Assets, total	602,680	596,549
Current liabilities
Accounts payable	9,273	11,049
Other current liabilities	104,566	132,784
Total current liabilities	113,839	143,833
Deferred tax liabilities	4,796	4,071
Other long-term liabilities	15,221	14,173
Stockholders' equity
Common stock, $0.001 par value; Authorized -- 50,000 shares, issued and outstanding 19,298 as of July 1, 2023 and 19,206 as of December 31, 2022	19	19
Additional paid-in capital	59,970	55,604
Retained earnings	427,311	391,636
Accumulated other comprehensive income (loss)	(18,476)	(12,787)
Total stockholders' equity	468,824	434,472
Liabilities and equity, total	$ 602,680	$ 596,549

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Jul. 01, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par or stated value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares, issued (in shares)	19,298	19,206
Common stock, shares, outstanding (in shares)	19,298	19,206

Condensed Consolidated Statemen

Condensed Consolidated Statements of Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Income Statement [Abstract]
Net sales	$ 238,202	$ 264,474	$ 486,562	$ 537,341
Cost of sales	43,326	49,517	91,845	100,900
Gross profit	194,876	214,957	394,717	436,441
Operating expenses:
Associate incentives	102,380	119,204	208,450	238,824
Selling, general and administrative	68,096	66,387	135,022	135,184
Total operating expenses	170,476	185,591	343,472	374,008
Earnings from operations	24,400	29,366	51,245	62,433
Other income (expense):
Interest income	2,224	673	3,999	1,412
Interest expense	(43)	(96)	(74)	(128)
Other, net	229	(635)	141	(1,122)
Other income (expense), net	2,410	(58)	4,066	162
Earnings before income taxes	26,810	29,308	55,311	62,595
Income taxes	9,518	10,151	19,636	20,969
Net earnings	$ 17,292	$ 19,157	$ 35,675	$ 41,626
Earnings per common share
Basic (in dollars per share)	$ 0.89	$ 1	$ 1.85	$ 2.16
Diluted (in dollars per share)	$ 0.89	$ 1	$ 1.84	$ 2.15
Weighted average common shares outstanding
Basic (in shares)	19,321	19,215	19,302	19,283
Diluted (in shares)	19,427	19,244	19,377	19,362
Comprehensive income:
Net earnings	$ 17,292	$ 19,157	$ 35,675	$ 41,626
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(7,957)	(11,672)	(6,303)	(12,363)
Tax benefit (expense) related to foreign currency translation adjustment	516	2,995	614	2,449
Other comprehensive income (loss), net of tax	(7,441)	(8,677)	(5,689)	(9,914)
Comprehensive income	$ 9,851	$ 10,480	$ 29,986	$ 31,712

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Jan. 01, 2022		19,393,000
Beginning balance at Jan. 01, 2022	$ 395,124	$ 19	$ 50,010	$ 344,637	$ 458
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	41,626			41,626
Other comprehensive income (loss), net of tax	(9,914)				(9,914)
Equity-based compensation expense	$ 6,739		6,739
Common stock repurchased and retired (in shares)	(288,000)	(288,000)
Common stock repurchased and retired	$ (25,382)		(3,031)	(22,351)
Common stock issued under equity award plans (in shares)		91,000
Common stock issued under equity award plans	0
Tax withholding for net-share settled equity awards	(4,512)		(4,512)
Ending balance (in shares) at Jul. 02, 2022		19,196,000
Ending balance at Jul. 02, 2022	403,681	$ 19	49,206	363,912	(9,456)
Beginning balance (in shares) at Apr. 02, 2022		19,185,000
Beginning balance at Apr. 02, 2022	389,946	$ 19	45,951	344,755	(779)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	19,157			19,157
Other comprehensive income (loss), net of tax	(8,677)				(8,677)
Equity-based compensation expense	$ 3,556		3,556
Common stock repurchased and retired (in shares)	0
Common stock issued under equity award plans (in shares)		11,000
Common stock issued under equity award plans	$ 0
Tax withholding for net-share settled equity awards	(301)		(301)
Ending balance (in shares) at Jul. 02, 2022		19,196,000
Ending balance at Jul. 02, 2022	$ 403,681	$ 19	49,206	363,912	(9,456)
Beginning balance (in shares) at Dec. 31, 2022	19,206,000	19,206,000
Beginning balance at Dec. 31, 2022	$ 434,472	$ 19	55,604	391,636	(12,787)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	35,675			35,675
Other comprehensive income (loss), net of tax	(5,689)				(5,689)
Equity-based compensation expense	7,282		7,282
Common stock issued under equity award plans (in shares)		92,000
Common stock issued under equity award plans	0
Tax withholding for net-share settled equity awards	$ (2,916)		(2,916)
Ending balance (in shares) at Jul. 01, 2023	19,298,000	19,298,000
Ending balance at Jul. 01, 2023	$ 468,824	$ 19	59,970	427,311	(18,476)
Beginning balance (in shares) at Apr. 01, 2023		19,294,000
Beginning balance at Apr. 01, 2023	455,354	$ 19	56,351	410,019	(11,035)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	17,292			17,292
Other comprehensive income (loss), net of tax	(7,441)				(7,441)
Equity-based compensation expense	$ 3,674		3,674
Common stock repurchased and retired (in shares)	0
Common stock issued under equity award plans (in shares)		4,000
Common stock issued under equity award plans	$ 0
Tax withholding for net-share settled equity awards	$ (55)		(55)
Ending balance (in shares) at Jul. 01, 2023	19,298,000	19,298,000
Ending balance at Jul. 01, 2023	$ 468,824	$ 19	$ 59,970	$ 427,311	$ (18,476)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022
Cash flows from operating activities
Net earnings	$ 35,675	$ 41,626
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities
Depreciation and amortization	6,519	6,628
Right-of-use asset amortization	3,846	4,105
(Gain) loss on sale of property and equipment	(12)	74
Equity-based compensation expense	7,282	6,739
Deferred income taxes	(5,026)	(6,825)
Changes in operating assets and liabilities:
Inventories	2,134	8,537
Prepaid expenses and other assets	1,986	(3,072)
Accounts payable	(1,171)	(3,711)
Other liabilities	(28,849)	(19,787)
Net cash provided by (used in) operating activities	22,384	34,314
Cash flows from investing activities
Proceeds from the settlement of net investment hedges	3,775	4,555
Payments for net investment hedge	(1,271)	0
Payments to acquire businesses	0	(6,532)
Proceeds from sale of property and equipment	13	3
Purchases of property and equipment	(5,716)	(3,535)
Net cash provided by (used in) investing activities	(3,199)	(5,509)
Cash flows from financing activities
Repurchase of common stock	0	(25,382)
Borrowings on line of credit	750	10,500
Payments on line of credit	(750)	(10,500)
Payments related to tax withholding for net-share settled equity awards	(2,916)	(4,512)
Payments for contingent consideration	(338)	0
Net cash provided by (used in) financing activities	(3,254)	(29,894)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(4,310)	(8,535)
Net increase (decrease) in cash, cash equivalents, and restricted cash	11,621	(9,624)
Cash, cash equivalents, and restricted cash at beginning of period	291,320	243,653
Cash, cash equivalents, and restricted cash at end of period	302,941	234,029
Reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
Cash and cash equivalents	300,183	230,370
Restricted cash included in other assets	2,758	3,659
Total cash, cash equivalents, and restricted cash	302,941	234,029
Cash paid during the period for:
Interest	3	45
Income taxes	28,817	31,523
Cash received during the period for:
Income tax refund	680	43
Non-cash investing and financing activities:
Right-of-use assets obtained in exchange for lease obligations	4,688	4,471
Accrued purchases of property and equipment	132	988
Contingent consideration given to acquire businesses	$ 0	$ 886

Organization, Consolidation, an

Organization, Consolidation, and Basis of Presentation	6 Months Ended
	Jul. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation, and Basis of Presentation	ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures high quality, science-based nutritional and personal care products. The Condensed Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, which are grouped and presented in two geographic regions: (1) Asia Pacific, and (2) Americas and Europe. Asia Pacific is further divided into three sub-regions: (i) Greater China, (ii) Southeast Asia Pacific, and (iii) North Asia. The countries included in these regions and sub-regions are described below: (1) Asia Pacific - (i) Greater China - Hong Kong, Taiwan, and China. The Company’s business in China is conducted by BabyCare Holdings, Ltd., the Company’s wholly-owned subsidiary. (ii) Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia. (iii) North Asia – Japan and South Korea. (2) Americas and Europe – United States, Canada, Mexico, Colombia, and Europe (the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands). The condensed consolidated balance sheet as of December 31, 2022, derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the SEC. Accordingly, certain information and disclosures that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of the Company’s management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company’s financial position as of July 1, 2023, and results of operations and cash flows for the three and six months ended July 1, 2023 and July 2, 2022. The interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto that are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The results of operations for the three and six months ended July 1, 2023, are not necessarily indicative of the results that may be expected for the fiscal year ending December 30, 2023. NOTE A – ORGANIZATION, CONSOLIDATION, AND BASIS OF PRESENTATION - CONTINUED Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. ASU 2021-08 requires an acquirer to recognize and measure contract assets and contract liabilities (deferred revenue) acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). Under this approach, the acquirer applies the revenue model as if it had originated the contracts. This is a departure from the current requirement to measure contract assets and contract liabilities at fair value at the acquisition date. ASU 2021-08 is effective for annual periods beginning after December 15, 2022 and interim periods within those annual periods. ASU 2021-08 should be applied prospectively to business combinations occurring on or after the date of adoption. Evaluation of this new standard is dependent on multiple circumstances including the timing and complexity of completed business combinations. The Company adopted ASU 2021-08 during the first quarter of 2023 and the adoption of the standard did not have an impact on its condensed consolidated financial statements. No other new accounting pronouncement issued or effective during the three and six months ended July 1, 2023, had, or is expected to have, a material impact on the Company's condensed consolidated financial statements.

Fair Value Measures

Fair Value Measures	6 Months Ended
	Jul. 01, 2023
Fair Value Disclosures [Abstract]
Fair Value Measures	FAIR VALUE MEASURES The Company measures at fair value certain of its financial and non-financial assets and liabilities by using a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, essentially an exit price, based on the highest and best use of the asset or liability. The levels of the fair value hierarchy are: • Level 1 inputs are quoted market prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2 inputs are from other than quoted market prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. • Level 3 inputs are unobservable and are used to measure fair value in situations where there is little, if any, market activity for the asset or liability at the measurement date. NOTE B – FAIR VALUE MEASURES - CONTINUED As of July 1, 2023, and December 31, 2022, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown: July 1, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 230,927 $ 230,927 $ — $ — Foreign currency contracts included in prepaid expenses and other current assets 639 — 639 — Deferred compensation liabilities included in other long-term liabilities (2,580) — (2,580) — December 31, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 211,539 $ 211,539 $ — $ — Foreign currency contracts included in other current liabilities (3,150) — (3,150) — Deferred compensation liabilities included in other long-term liabilities (1,632) — (1,632) — Contingent consideration included in other current liabilities of ($338) and other long-term liabilities of ($548) (886) — — (886) There were no transfers of financial assets or liabilities between levels of the fair value hierarchy for the periods indicated. The majority of the Company’s non-financial assets, which include long-lived assets, are not required to be carried at fair value on a recurring basis. However, if an impairment charge is required, a non-financial asset would be written down to fair value. As of July 1, 2023 and December 31, 2022, there were no non-financial assets measured at fair value on a non-recurring basis. As of July 1, 2023 and December 31, 2022, the Company’s financial instruments include cash equivalents and restricted cash. The recorded values of cash equivalents and restricted cash approximate their fair values, based on their short-term nature. three

Inventories

Inventories	6 Months Ended
	Jul. 01, 2023
Inventory Disclosure [Abstract]
Inventories	INVENTORIES Inventories consist of the following: July 1, December 31, Raw materials $ 20,544 $ 21,776 Work in progress 3,725 4,285 Finished goods 37,693 41,028 Inventories $ 61,962 $ 67,089 Noncurrent inventories $ 4,390 $ 3,479 As of July 1, 2023, noncurrent inventories consisted of $2,400 of raw materials and $1,990 of finished goods inventory. As of December 31, 2022, noncurrent inventories consisted of $1,711 of raw materials and $1,768 of finished goods inventory. Noncurrent inventories are included in the “Other assets” line item on the Company’s condensed consolidated balance sheets. Noncurrent inventory is anticipated to be consumed beyond our normal operating cycle, but prior to obsolescence.

Investment in Equity Securities

Investment in Equity Securities	6 Months Ended
	Jul. 01, 2023
Equity [Abstract]
Investments in Equity Securities	INVESTMENT IN EQUITY SECURITIES As of July 1, 2023 and December 31, 2022, the carrying amount of equity securities without readily determinable fair values wa s $20,000 and is included in the “Other assets” line item on the Company’s condensed consolidated balance sheets.

Revenue and Contract Liabilitie

Revenue and Contract Liabilities	6 Months Ended
	Jul. 01, 2023
Revenue from Contract with Customer [Abstract]
Revenue and Contract Liabilities	REVENUE AND CONTRACT LIABILITIES Revenue is recognized when, or as, control of a promised product or service transfers to a customer, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for transferring those products or services. A majority of the Company’s sales are for products sold at a point in time and shipped to customers, for which control is transferred as goods are delivered to the third-party carrier for shipment. The Company receives payment, primarily via credit card, for the sale of products at the time customers place orders and payment is required prior to shipment. Contract liabilities, which are recorded within the “Other current liabilities” line item in the condensed consolidated balance sheets, primarily relate to deferred revenue for product sales for customer payments received in advance of shipment, for outstanding material rights under the initial order program, and for services where control is transferred over time as services are delivered. Other revenue includes fees, which are paid by the customer at the beginning of the service period, for access to online customer service applications and annual account renewal fees for Associates, for which control is transferred over time as services are delivered and are recognized as revenue on a straight-line basis over the term of the respective contracts. The following table presents Other Revenue for the periods indicated: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Other Revenue $ 755 $ 895 $ 1,481 $ 1,794 NOTE E – REVENUE AND CONTRACT LIABILITIES - CONTINUED Disaggregation of revenue by geographic region and major product line is included in Segment Information in Note J. The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period: July 1, December 31, Contract liabilities at beginning of period $ 20,875 $ 19,635 Increase due to deferral of revenue at end of period 10,969 20,875 Decrease due to beginning contract liabilities recognized as revenue (18,336) (19,635) Contract liabilities at end of period $ 13,508 $ 20,875

Line of Credit

Line of Credit	6 Months Ended
	Jul. 01, 2023
Line of Credit Facility [Abstract]
Line of Credit	LINE OF CREDIT On August 25, 2020, the Company as borrower, and certain of its material subsidiaries as guarantors, entered into the Second Amended and Restated Credit Agreement (the “Credit Agreement ” ) with Bank of America, N.A. (“Bank of America ” ) as Administrative Agent, Swingline Lender and Letter of Credit Issuer, and the other lenders party thereto. On August 10, 2022, the Company entered into the Second Amendment to the Second Amended and Restated Credit Agreement ("Restated Credit Agreement"), which replaces the Eurodollar Rate, and LIBOR terms and provisions with the Bloomberg Short-Term Bank Yield Index rate (" BSBY"). The Credit Agreement provides for a revolving credit limit for loans to the Company up to $75,000 (the “Credit Facility ” ). In addition, at the option of the Company, and subject to certain conditions, the Company may request to increase the aggregate commitment under the Credit Facility up to an additional $200,000. There was no outstanding debt balance on the Credit Facility as of July 1, 2023 and December 31, 2022. The obligations of the Company under the Credit Agreement are secured by the pledge of the capital stock of certain subsidiaries of the Company, pursuant to a Security and Pledge Agreement. Interest on revolving borrowings under the Credit Facility is computed at BSBY , adjusted by features specified in the Credit Agreement. The Credit Agreement covenants require the Company’s rolling four-quarter consolidated EBITDA (per the credit agreement) to be $100,000 or greater and its ratio of consolidated funded debt to consolidated EBITDA to be equal to or less than 2.0 to 1.0 at the end of each quarter. The Credit Agreement does not include any restrictions on the payment of cash dividends or share repurchases by the Company. Consolidated EBITDA and consolidated funded debt are non-GAAP terms. The Company will be required to pay any balance on this Credit Facility in full at the time of maturity in August 2025.

Contingencies

Contingencies	6 Months Ended
	Jul. 01, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES The Company is involved in various lawsuits, claims, and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving its products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company records a liability when a particular contingency is probable and estimable. The Company faces contingencies that are reasonably possible to occur; however, they cannot currently be estimated. While complete assurance cannot be given as to the outcome of these proceedings, management does not currently believe that any of these matters, individually or in the aggregate, will have a material adverse effect on the Company’s financial condition, liquidity or results of operations. It is reasonably possible that a change in the contingencies could result in a change in the amount recorded by the Company in the future.

Derivative Financial Instrument

Derivative Financial Instruments	6 Months Ended
	Jul. 01, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	DERIVATIVE FINANCIAL INSTRUMENTS The Company’s risk management strategy includes the select use of derivative instruments to reduce the effects of volatility in foreign currency exchange exposure on operating results and cash flows. In accordance with the Company’s risk management policies, the Company does not hold or issue derivative instruments for trading or speculative purposes. The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. When the Company becomes a party to a derivative instrument and intends to apply hedge accounting, the Company formally documents the hedge relationship and the risk management objective for undertaking the hedge, the nature of risk being hedged, and the hedged transaction, which includes designating the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. The Company also documents how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company periodically uses derivative instruments to hedge the foreign currency exposure of its net investment in foreign subsidiaries into U.S. dollars. Initially, the Company records derivative assets on a gross basis in its condensed consolidated balance sheets. Subsequently the fair value of derivatives is measured for each reporting period. The effective portion of gains and losses attributable to these net investment hedges is recorded to foreign currency translation adjustment (“FCTA”) within accumulated other comprehensive income (loss) (“AOCI”) to offset the change in the carrying value of the net investment being hedged and will subsequently be reclassified to net earnings in the period in which the investment in the subsidiary is either sold or substantially liquidated.

Common Stock and Earnings Per S

Common Stock and Earnings Per Share	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Common Stock and Earnings Per Share	COMMON STOCK AND EARNINGS PER SHARE Basic earnings per share (“EPS”) is based on the weighted-average number of shares outstanding for each period. Shares that have been repurchased and retired during the periods specified below have been included in the calculation of the number of weighted-average shares that are outstanding for the calculation of basic EPS based on the time they were outstanding in any period. Diluted EPS is based on shares that are outstanding (computed under basic EPS) and on potentially dilutive shares. Shares that are included in the diluted EPS calculations under the treasury stock method include equity awards that are in-the-money but have not yet been exercised. The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net earnings available to common shareholders $ 17,292 $ 19,157 $ 35,675 $ 41,626 Weighted average common shares outstanding - basic 19,321 19,215 19,302 19,283 Dilutive effect of in-the-money equity awards 106 29 75 79 Weighted average common shares outstanding - diluted 19,427 19,244 19,377 19,362 Earnings per common share from net earnings - basic $ 0.89 $ 1.00 $ 1.85 $ 2.16 Earnings per common share from net earnings - diluted $ 0.89 $ 1.00 $ 1.84 $ 2.15 NOTE I – COMMON STOCK AND EARNINGS PER SHARE - CONTINUED Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, 354 374 325 272 There were no shares repurchased during the three months ended July 1, 2023 and July 2, 2022. There were no shares repurchased during the six months ended July 1, 2023. During the six months ended July 2, 2022, the Company repurchased and retired 288 shares for $25,382 under the Company's share repurchase plan. The excess of the repurchase price over par value is allocated between additional paid-in capital and retained earnings on a pro-rata basis. The purchase of shares under this plan reduces the number of shares outstanding in the above calculations.

Segment Information

Segment Information	6 Months Ended
	Jul. 01, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company primarily operates as a global direct-selling nutrition, personal health and wellness company that develops and manufactures high quality, science-based nutritional, and personal care products. The Company’s operating segments are identified according to how business activities are managed and evaluated by the chief operating decision maker (“CODM”), our CEO. The CODM manages the business, allocates resources, makes operating decisions, and evaluates performance for a geographic region or market based on net sales. The Company aggregates its direct-selling operating segments (“Direct-selling”) into one reportable segment, as management believes that the Company’s Direct-selling segments exhibit similar long-term financial performance and have similar economic characteristics. The CODM does not evaluate operating segments using asset information, accordingly, the Company does not report asset information by segment. As a result of the Company’s acquisitions during 2022, the Company has operating segments that are not material to the Company’s net sales. These operating segments are included as a component of (“All other”) and are included for purposes of reconciliation of net sales to the Company’s Condensed Consolidated Statements of Comprehensive Income. Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net Sales: Direct-selling $ 236,795 $ 264,474 $ 483,675 $ 537,341 All other 1,407 — 2,887 — Consolidated Total $ 238,202 $ 264,474 $ 486,562 $ 537,341 No single Associate accounted for 10% or more of net sales for the periods presented. The table below summarizes the approximate percentage of total product revenue for our Direct-selling segment that has been contributed by the Company’s nutritionals, food, and personal care and skincare products for the periods indicated. NOTE J – SEGMENT INFORMATION - CONTINUED Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, USANA® Nutritionals 87 % 85 % 87 % 86 % USANA Foods(1) 7 % 8 % 7 % 7 % Personal care and Skincare 5 % 6 % 5 % 6 % All Other 1 % 1 % 1 % 1 % (1) Includes the Company’s Active Nutrition line. Selected Financial Information Financial information, presented by geographic region is listed below: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net Sales to External Customers Asia Pacific Greater China $ 128,749 $ 140,775 $ 252,569 $ 274,514 Southeast Asia Pacific 39,337 47,830 85,623 102,572 North Asia 25,529 28,803 55,137 58,742 Asia Pacific Total 193,615 217,408 393,329 435,828 Americas and Europe 44,587 47,066 93,233 101,513 Consolidated Total $ 238,202 $ 264,474 $ 486,562 $ 537,341 The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net sales: China $ 117,882 $ 128,389 $ 227,915 $ 248,643 South Korea $ 24,906 $ 28,153 $ 53,792 $ 57,340 United States $ 23,681 $ 24,584 $ 49,666 $ 52,861 As of July 1, December 31, Long-lived assets: United States $ 88,717 $ 89,150 China $ 77,427 $ 83,938

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Pay vs Performance Disclosure
Net earnings	$ 17,292	$ 19,157	$ 35,675	$ 41,626

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jul. 01, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Organization, Consolidation, _2

Organization, Consolidation, and Basis of Presentation (Policies)	6 Months Ended
	Jul. 01, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	USANA Health Sciences, Inc. is a global direct-selling, personal health and wellness company that develops and manufactures high quality, science-based nutritional and personal care products. The Condensed Consolidated Financial Statements (the “Financial Statements”) include the accounts and operations of the Company, which are grouped and presented in two geographic regions: (1) Asia Pacific, and (2) Americas and Europe. Asia Pacific is further divided into three sub-regions: (i) Greater China, (ii) Southeast Asia Pacific, and (iii) North Asia. The countries included in these regions and sub-regions are described below: (1) Asia Pacific - (i) Greater China - Hong Kong, Taiwan, and China. The Company’s business in China is conducted by BabyCare Holdings, Ltd., the Company’s wholly-owned subsidiary. (ii) Southeast Asia Pacific – Australia, New Zealand, Singapore, Malaysia, the Philippines, Thailand, and Indonesia. (iii) North Asia – Japan and South Korea. (2) Americas and Europe – United States, Canada, Mexico, Colombia, and Europe (the United Kingdom, France, Germany, Spain, Italy, Romania, Belgium, and the Netherlands).
Consolidation, Policy	The condensed consolidated balance sheet as of December 31, 2022, derived from audited consolidated financial statements, and the unaudited interim condensed consolidated financial information of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X promulgated by the SEC. Accordingly, certain information and disclosures that are normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations.
Use of Estimates, Policy	The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. In the opinion of the Company’s management, the accompanying interim condensed consolidated financial information contains all adjustments, consisting only of normal recurring adjustments that are necessary to state fairly the Company’s financial position as of July 1, 2023, and results of operations and cash flows for the three and six months ended July 1, 2023 and July 2, 2022.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. ASU 2021-08 requires an acquirer to recognize and measure contract assets and contract liabilities (deferred revenue) acquired in a business combination in accordance with Revenue from Contracts with Customers (Topic 606). Under this approach, the acquirer applies the revenue model as if it had originated the contracts. This is a departure from the current requirement to measure contract assets and contract liabilities at fair value at the acquisition date. ASU 2021-08 is effective for annual periods beginning after December 15, 2022 and interim periods within those annual periods. ASU 2021-08 should be applied prospectively to business combinations occurring on or after the date of adoption. Evaluation of this new standard is dependent on multiple circumstances including the timing and complexity of completed business combinations. The Company adopted ASU 2021-08 during the first quarter of 2023 and the adoption of the standard did not have an impact on its condensed consolidated financial statements. No other new accounting pronouncement issued or effective during the three and six months ended July 1, 2023, had, or is expected to have, a material impact on the Company's condensed consolidated financial statements.

Fair Value Measures (Tables)

Fair Value Measures (Tables)	6 Months Ended
	Jul. 01, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities	As of July 1, 2023, and December 31, 2022, the following financial assets and liabilities were measured at fair value on a recurring basis using the type of inputs shown: July 1, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 230,927 $ 230,927 $ — $ — Foreign currency contracts included in prepaid expenses and other current assets 639 — 639 — Deferred compensation liabilities included in other long-term liabilities (2,580) — (2,580) — December 31, Fair Value Measurements Using Inputs Level 1 Level 2 Level 3 Money market funds included in cash equivalents $ 211,539 $ 211,539 $ — $ — Foreign currency contracts included in other current liabilities (3,150) — (3,150) — Deferred compensation liabilities included in other long-term liabilities (1,632) — (1,632) — Contingent consideration included in other current liabilities of ($338) and other long-term liabilities of ($548) (886) — — (886)

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jul. 01, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: July 1, December 31, Raw materials $ 20,544 $ 21,776 Work in progress 3,725 4,285 Finished goods 37,693 41,028 Inventories $ 61,962 $ 67,089 Noncurrent inventories $ 4,390 $ 3,479

Revenue and Contract Liabilit_2

Revenue and Contract Liabilities (Tables)	6 Months Ended
	Jul. 01, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Other Revenue	The following table presents Other Revenue for the periods indicated: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Other Revenue $ 755 $ 895 $ 1,481 $ 1,794
Schedule of Contract Liabilities from Contracts with Customers	The following table provides information about contract liabilities from contracts with customers, including significant changes in the contract liabilities balances during the period: July 1, December 31, Contract liabilities at beginning of period $ 20,875 $ 19,635 Increase due to deferral of revenue at end of period 10,969 20,875 Decrease due to beginning contract liabilities recognized as revenue (18,336) (19,635) Contract liabilities at end of period $ 13,508 $ 20,875

Common Stock and Earnings Per_2

Common Stock and Earnings Per Share (Tables)	6 Months Ended
	Jul. 01, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earnings Per Share	The following is a reconciliation of the numerator and denominator used to calculate basic EPS and diluted EPS for the periods indicated: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net earnings available to common shareholders $ 17,292 $ 19,157 $ 35,675 $ 41,626 Weighted average common shares outstanding - basic 19,321 19,215 19,302 19,283 Dilutive effect of in-the-money equity awards 106 29 75 79 Weighted average common shares outstanding - diluted 19,427 19,244 19,377 19,362 Earnings per common share from net earnings - basic $ 0.89 $ 1.00 $ 1.85 $ 2.16 Earnings per common share from net earnings - diluted $ 0.89 $ 1.00 $ 1.84 $ 2.15
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Equity awards for the following shares were not included in the computation of diluted EPS due to the fact that their effect would be anti-dilutive: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, 354 374 325 272

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jul. 01, 2023
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	These operating segments are included as a component of (“All other”) and are included for purposes of reconciliation of net sales to the Company’s Condensed Consolidated Statements of Comprehensive Income. Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net Sales: Direct-selling $ 236,795 $ 264,474 $ 483,675 $ 537,341 All other 1,407 — 2,887 — Consolidated Total $ 238,202 $ 264,474 $ 486,562 $ 537,341
Revenue from External Customers by Products and Services	Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, USANA® Nutritionals 87 % 85 % 87 % 86 % USANA Foods(1) 7 % 8 % 7 % 7 % Personal care and Skincare 5 % 6 % 5 % 6 % All Other 1 % 1 % 1 % 1 % (1) Includes the Company’s Active Nutrition line.
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area	Financial information, presented by geographic region is listed below: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net Sales to External Customers Asia Pacific Greater China $ 128,749 $ 140,775 $ 252,569 $ 274,514 Southeast Asia Pacific 39,337 47,830 85,623 102,572 North Asia 25,529 28,803 55,137 58,742 Asia Pacific Total 193,615 217,408 393,329 435,828 Americas and Europe 44,587 47,066 93,233 101,513 Consolidated Total $ 238,202 $ 264,474 $ 486,562 $ 537,341
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following table provides further information on markets representing ten percent or more of consolidated net sales and long-lived assets, respectively: Quarter Ended Six Months Ended July 1, July 2, July 1, July 2, Net sales: China $ 117,882 $ 128,389 $ 227,915 $ 248,643 South Korea $ 24,906 $ 28,153 $ 53,792 $ 57,340 United States $ 23,681 $ 24,584 $ 49,666 $ 52,861 As of July 1, December 31, Long-lived assets: United States $ 88,717 $ 89,150 China $ 77,427 $ 83,938

Organization, Consolidation, _3

Organization, Consolidation, and Basis of Presentation (Details)	6 Months Ended
	Jul. 01, 2023 region
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of geographic regions	2
Number of sub geographical regions	3

Fair Value Measures - Schedule

Fair Value Measures - Schedule Of Assets And Liabilities Measured At Fair Value (Details) - USD ($) $ in Thousands	Jul. 01, 2023	Dec. 31, 2022
Fair Value Disclosures [Line Items]
Deferred compensation liabilities included in other long-term liabilities		$ (1,632)
Contingent consideration, liability, current		(338)
Contingent consideration, liability, noncurrent		(548)
Fair Value, Recurring
Fair Value Disclosures [Line Items]
Foreign currency contracts included in prepaid expenses and other current assets	$ 639
Foreign currency contracts included in other current liabilities		3,150
Deferred compensation liabilities included in other long-term liabilities	(2,580)	(1,632)
Contingent consideration, liability		(886)
Fair Value, Recurring | Level 1
Fair Value Disclosures [Line Items]
Foreign currency contracts included in prepaid expenses and other current assets	0
Foreign currency contracts included in other current liabilities		0
Deferred compensation liabilities included in other long-term liabilities	0	0
Contingent consideration, liability		0
Fair Value, Recurring | Level 2
Fair Value Disclosures [Line Items]
Foreign currency contracts included in prepaid expenses and other current assets	639
Foreign currency contracts included in other current liabilities		3,150
Deferred compensation liabilities included in other long-term liabilities	(2,580)
Contingent consideration, liability		0
Fair Value, Recurring | Level 3
Fair Value Disclosures [Line Items]
Foreign currency contracts included in prepaid expenses and other current assets	0
Foreign currency contracts included in other current liabilities		0
Deferred compensation liabilities included in other long-term liabilities	0	0
Contingent consideration, liability		(886)
Fair Value, Recurring | Money Market Funds
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	230,927	211,539
Fair Value, Recurring | Money Market Funds | Level 1
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	230,927	211,539
Fair Value, Recurring | Money Market Funds | Level 2
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	0	0
Fair Value, Recurring | Money Market Funds | Level 3
Fair Value Disclosures [Line Items]
Money market funds included in cash equivalents	$ 0	$ 0

Fair Value Measures - Narrative

Fair Value Measures - Narrative (Details) - USD ($)	6 Months Ended
	Jul. 01, 2023	Dec. 31, 2022
Fair Value Disclosures [Line Items]
Contingent consideration, liability, milestone period	3 years
Fair Value, Recurring
Fair Value Disclosures [Line Items]
Nonfinancial assets, fair value disclosure	$ 0	$ 0

Inventories - Schedule of Inven

Inventories - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jul. 01, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 20,544	$ 21,776
Work in progress	3,725	4,285
Finished goods	37,693	41,028
Inventories	61,962	67,089
Noncurrent inventories	$ 4,390	$ 3,479

Inventories - Narrative (Detail

Inventories - Narrative (Details) - USD ($) $ in Thousands	Jul. 01, 2023	Dec. 31, 2022
Inventory [Line Items]
Noncurrent inventories	$ 4,390	$ 3,479
Raw Materials
Inventory [Line Items]
Noncurrent inventories	2,400	1,711
Finished Goods
Inventory [Line Items]
Noncurrent inventories	$ 1,990	$ 1,768

Investment in Equity Securiti_2

Investment in Equity Securities - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 01, 2023	Jul. 01, 2023	Dec. 31, 2022
Equity [Line Items]
Impairment of securities	$ 0	$ 0	$ 0
Other Assets
Equity [Line Items]
Equity securities without readily determinable fair value	$ 20,000,000	$ 20,000,000	$ 20,000,000

Revenue and Contract Liabilit_3

Revenue and Contract Liabilities - Schedule of Other Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Revenue from Contract with Customer [Abstract]
Other Revenue	$ 755	$ 895	$ 1,481	$ 1,794

Revenue and Contract Liabilit_4

Revenue and Contract Liabilities - Schedule Of Contract Liabilities From Contract With Customers (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jul. 01, 2023	Dec. 31, 2022
Movement in Contract Liabilities [Roll Forward]
Contract liabilities at beginning of period	$ 20,875	$ 19,635
Increase due to deferral of revenue at end of period	10,969	20,875
Decrease due to beginning contract liabilities recognized as revenue	(18,336)	(19,635)
Contract liabilities at end of period	$ 13,508	$ 20,875

Line of Credit (Details)

Line of Credit (Details) - Line of Credit	6 Months Ended
	Jul. 01, 2023 USD ($)	Dec. 31, 2022 USD ($)
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity	$ 75,000,000
Line of credit facility, additional increase in maximum borrowing capacity	200,000,000
Outstanding debt	0	$ 0
Amended and Restated Credit Agreement
Line of Credit Facility [Line Items]
Debt instrument covenant, EBITDA	$ 100,000,000
Ratio of consolidated funded debt to EBITDA (less than)	2

Derivative Financial Instrume_2

Derivative Financial Instruments - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Derivative [Line Items]
Gain on derivative	$ 2,504	$ 4,555	$ 2,504	$ 4,555
Foreign Exchange Option | Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount	$ 81,343		$ 81,343
Foreign Exchange Forward | Designated as Hedging Instrument
Derivative [Line Items]
Derivative notional amount		$ 98,930		$ 98,930

Common Stock and Earnings Per_3

Common Stock and Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Earnings Per Share [Abstract]
Net earnings available to common shareholders	$ 17,292	$ 19,157	$ 35,675	$ 41,626
Weighted average common shares outstanding - basic (in shares)	19,321	19,215	19,302	19,283
Dilutive effect of in-the-money equity awards (in shares)	106	29	75	79
Weighted average common shares outstanding - diluted (in shares)	19,427	19,244	19,377	19,362
Earnings per common share from net earnings - basic (in dollars per share)	$ 0.89	$ 1	$ 1.85	$ 2.16
Earnings per common share from net earnings - diluted (in dollars per share)	$ 0.89	$ 1	$ 1.84	$ 2.15

Common Stock and Earnings Per_4

Common Stock and Earnings Per Share - Schedule of Shares not Included in the Computation of Diluted EPS (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	354	374	325	272

Common Stock and Earnings Per_5

Common Stock and Earnings Per Share - Narrative (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 02, 2022
Earnings Per Share [Abstract]
Common stock repurchased and retired (in shares)	0	0	288
Common stock repurchased and retired			$ 25,382
Remaining authorized repurchase amount	$ 82,839

Segment Information - Narrative

Segment Information - Narrative (Details)	6 Months Ended
	Jul. 01, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments	1

Segment Information - Schedule

Segment Information - Schedule of Segment Reporting Information, by Operating Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
Segment Information [Line Items]
Net sales	$ 238,202	$ 264,474	$ 486,562	$ 537,341
Operating Segments | Direct Selling
Segment Information [Line Items]
Net sales	236,795	264,474	483,675	537,341
Operating Segments | All Other
Segment Information [Line Items]
Net sales	$ 1,407	$ 0	$ 2,887	$ 0

Segment Information - Schedul_2

Segment Information - Schedule of Revenue Percentage By Product (Details) - Product Concentration Risk - Revenue Benchmark	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022
USANA® Nutritionals
Segment Information [Line Items]
Concentration risk, percentage	87%	85%	87%	86%
USANA Foods
Segment Information [Line Items]
Concentration risk, percentage	7%	8%	7%	7%
Personal care and Skincare
Segment Information [Line Items]
Concentration risk, percentage	5%	6%	5%	6%
All Other
Segment Information [Line Items]
Concentration risk, percentage	1%	1%	1%	1%

Segment Information - Consolida

Segment Information - Consolidated Net Sales and Long Lived Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jul. 01, 2023	Jul. 02, 2022	Jul. 01, 2023	Jul. 02, 2022	Dec. 31, 2022
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	$ 238,202	$ 264,474	$ 486,562	$ 537,341
Asia Pacific Total
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	193,615	217,408	393,329	435,828
Greater China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	128,749	140,775	252,569	274,514
Southeast Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	39,337	47,830	85,623	102,572
North Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	25,529	28,803	55,137	58,742
Americas and Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	44,587	47,066	93,233	101,513
China
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	117,882	128,389	227,915	248,643
Long-lived assets:	77,427		77,427		$ 83,938
South Korea
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	24,906	28,153	53,792	57,340
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net sales	23,681	$ 24,584	49,666	$ 52,861
Long-lived assets:	$ 88,717		$ 88,717		$ 89,150